Publications
2026
56. Kruf S, Delahaije RJBM, Fujita M, Büll C. Programmable HMO biosynthesis enabled by human cell-based glycoengineering. Glycobiology. 2026. cwag066. doi.org/10.1093/glycob/cwag066
55. Goerdeler F, Narimatsu Y, Büll C. Cell-based mucin arrays. Methods in Enzymology. 2026. 732:177-218. doi.org/10.1016/bs.mie.2026.03.006
54. Kruf S, Delahaije RJBM, Mohamed KA, Schoemaker B, Narimatsu Y, Clausen H, Triantis V, Boltje TJ, Büll C. Biosynthesis of human milk oligosaccharides (HMOs) in glycoengineered human cells. Glycobiology. 2026. 36(8):cwag048. doi.org/10.1093/glycob/cwag048
53. van Eck van der Sluijs J, Valk AHC, Houtum E, Kers-Rebel E, Looman M, Hobo W, Marneth A, Dolstra H, van den Boogaard L, Büll C, Cornelissen LAM, Adema GJ. Sialic acid cis-ligand dynamics modulate Siglec-7 and 9 function and affect Siglec7/9 co-blockade to potentiate NK cell anti-tumor activity. Oncoimmunology. 2026. 15(1):2649988. doi.org/10.1080/2162402X.2026.2649988
52. Narimatsu Y, Pleguezuelos-Manzano C, Hornikx DLAH, Goerdeler F, Jaroentomeechai T, Flores K, Narimatsu S, Boot C, Hansen L, Durbesson F, Vincentelli R, Comstock LE, Clevers H, Taleb V, Corzana F, Henrissat B, Clausen H, Hurtado-Guerrero R, Büll C. Discovery of a Bacteroides fragilis mucinase that cleaves bis-T O-glycans through a CBM32-dependent mechanism. Gut Microbes. 2026. 18(1):2644983. doi.org/10.1080/19490976.2026.2644983
51. Goerdeler F, Hornikx DL, Chien YC, de Wit D, Jaroentomeechai T, Jaeger M, Furukawa S, Tseng HC, Khoo KH, Jung J, Schmidt EN, Miller RL, Macauley M, Clausen H, Büll C, Narimatsu Y. Siglec-7 and -15 recognize repeated clustered sulfo-ST O-glycan motifs on select O-glycoproteins. bioRxiv. 2026.
2025
50. Jaroentomeechai T, Veloz B, Soares CO, Goerdeler F, Grosso AS, Büll C, Miller RL, Furukawa S, Ginés-Alcober I, Taleb V, Merino P, Ghirardello M, Compañón I, Coelho H, Dias JS, Vincentelli R, Henrissat B, Joshi H, Clausen H, Corzana F, Marcelo F, Hurtado-Guerrero R, Narimatsu Y. Microbial binding module employs sophisticated clustered saccharide patches to selectively adhere to mucins. Nature Communications. 2025. 16(1):9058. doi.org/10.1038/s41467-025-63756-w
49. Visser EA, Hornikx DL, Rahm M, Öztürk O, Psomiadou V, Calzari M, Mennen C, Moons SJ, Jaeger M, Lefeber DJ, Büll C, Boltje TJ. Insights into the utilization of sialic acid mimetics by mammalian cell lines. RSC Chemical Biology. 2025. 7(1):144-152. doi.org/10.1039/d5cb00193e
48. Kim S, Choi YG, Janssen K, Langenbach JWH, van den Brink DJ, Büll C, Joshi BS, Pomorski A, Raz V, Tanenbaum ME, Miesen P, Li Z, Joo C. RNA-associated glycoconjugates highlight potential ambiguities in glycoRNA analysis. Experimental & Molecular Medicine. 2025. 57(11):2619-2628. doi.org/10.1038/s12276-025-01585-z
2024
47. Narimatsu Y, Büll C, Taleb V, Liao Q, Compañón I, Sánchez-Navarro D, Durbesson F, Vincentelli R, Hansen L, Corzana F, Rovira C, Henrissat B, Clausen H, Joshi HJ, Hurtado-Guerrero R. A family of di-glutamate mucin degrading enzymes that bridges glycan hydrolases and peptidases. Nature Catalysis. 2024. 7:386-400. doi.org/10.1038/s41929-024-01116-5
46. Hodgson K, Orozco-Moreno M, Goode EA, Fisher M, Garnham R, Beatson R, Turner H, Livermore K, Zhou Y, Wilson L, Visser EA, Pijnenborg JFA, Eerden N, Moons SJ, Rossing E, Hysenaj G, Krishna R, Pen Z, Putri Nangkana K, Schmidt EN, Duxfield A, Dennis EP, Heer R, Lawson MA, Macauley M, Elliott DJ, Büll C, Scott E, Boltje TJ, Drake RR, Wang N, Munkley J. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. eBioMedicine. 2024. 104:105163. doi.org/10.1016/j.ebiom.2024.105163
45. Mohamed KA, Kruf S, Büll C. Putting a cap on the glycome: Dissecting human sialyltransferase functions. Carbohydrate Research. 2024. 544:109242. doi.org/10.1016/j.carres.2024.109242
2023
44. Madriz Sørensen D, Büll C, Madsen TD, Lira-Navarrete E, Mandel Clausen T, Clark AE, Garretson AF, Karlsson R, Pijnenborg JFA, Yin X, Miller RL, Chanda SK, Boltje TJ, Schjoldager KT, Vakhrushev SY, Halim A, Esko JD, Carlin AF, Hurtado-Guerrero R, Weigert R, Clausen H, Narimatsu Y. Identification of global inhibitors of cellular glycosylation. Nature Communications. 2023. 14(1):948. doi.org/10.1038/s41467-023-36598-7
43. van Houtum EJH, Kers-Rebel ED, Looman MW, Hooijberg E, Büll C, Granado D, Cornelissen LAM, Adema GJ. Tumor-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7. Cellular and Molecular Life Sciences. 2023. 80(6):169. doi.org/10.1007/s00018-023-04816-6
42. Moons SJ, Hornikx DL, Aasted, MKM, Pijnenborg JFA, Calzari M, White PB, Narimatsu Y, Clausen H, Wandall HH, Boltje TJ, Büll C. UV Light-induced spatial loss of sialic acid capping using a photoactivatable sialyltransferase inhibitor. RSC Chemical Biology. 2023. 4(7):506-511. doi.org/10.1039/d3cb00006k
41. Orozco-Moreno M, Visser EA, Hodgson K, Hipgrave Ederveen AL, Bastian K, Archer Goode E, Özturk Ö, Pijnenborg JFA, Eerden N, Moons SJ, Rossing E, Wang N, de Haan N, Büll C, Boltje TJ, Munkley J. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors. Glycobiology. 2023. 33(12):1155-1171. doi.org/10.1093/glycob/cwad085
40. Hornikx DL, Visser EA, Psomiadou V, Büll C, Boltje TJ. Engineering the sialome of mammalian cells with sialic acid mimetics. STAR Protocols. 2023. 4(3):102330. doi.org/10.1016/j.xpro.2023.102330
39. Poelaert KCK, van Kleef RGDM, Liu M, van Vliet A, Lyoo H, Gerber LS, Narimatsu Y, Büll C, Clausen H, de Vries E, Westerink RHS, van Kuppeveld FJM. Enterovirus D-68 infection of primary rat cortical neurons: Entry, replication and functional consequences. mBio. 2023. 14(2):e0024523. doi.org/10.1128/mbio.00245-23
2022
38. Sun L, Konstantinidi A, Ye Z, Nason R, Zhang Y, Büll C, Kahl-Knutson B, Hansen L, Leffler H, Vakhrushev SY, Yang Z, Clausen H, Narimatsu Y. Installation of O-glycan sulfation capacities in human HEK293 cells. Journal of Biological Chemistry. 2022. 298(2):101382. doi.org/10.1016/j.jbc.2021.101382
37. Moons SJ, Rossing E, Janssen MA, Büll C, Adema GJ, Boltje TJ. The Structure – activity relationship of sialic acid glycomimetics. ACS Chemical Biology. 2022. 17(3):590-597. doi.org/10.1021/acschembio.1c00868
36. Liu M, Huang L, Smits AA, Büll C, Narimatsu Y, van Kuppeveld FJ, Clausen H, de Haan CA, de Vries E. Avian-type receptors contribute to human Influenza virus A binding and entry by hetero-multivalent interactions. Nature Communications. 2022. 13(1):4054. doi.org/10.1038/s41467-022-31840-0
35. Balneger N, Cornelissen LAM, Wassink M, Moons SJ, Boltje TJ, Bar-Ephraim YE, Das KK, Søndergaard JN, Büll C, Adema GJ. Sialic acid blockade in dendritic cells enhances CD8+ T cell responses by facilitating high avidity interactions. Cellular and Molecular Life Sciences. 2022. 79(2):98. doi.org/10.1007/s00018-021-04027-x
34. van Scherpenzeel M, Conte F, Büll C, Ashikov A, Hermans E, Willems A, van Tol W, Kragt E, Noga M, Moret EE, Heise T, Langereis JD, Rossing E, Zimmermann M, Rubio-Gozalbo EM, de Jonge MI, Adema GJ, Zamboni N, Boltje TJ, Lefeber DJ. Dynamic tracing of sugar metabolism reveals the mechanisms of action of synthetic sugar analogs. Glycobiology. 2022. 32(3):239-250. doi.org/10.1093/glycob/cwab106
2021
33. Büll C, Nason R, Sun L, van Coillie J, Madriz Sørensen DM, Moons SJ, Yang Z, Arbitman S, Fernandes MF, Furukawa S, McBride R, Nycholat CM, Adema GJ, Paulson JC, Schnaar RL, Boltje TJ, Clausen H, Narimatsu Y. Probing the binding specificities of human siglecs by cell-based glycan arrays. Proceedings of the National Academy of Sciences. 2021. 118(17):e2026102118. doi.org/10.1073/pnas.2026102118
32. Nason R, Büll C, Konstantinidi A, Sun L, Ye Z, Halim A, Du W, Sørensen DM, Durbesson F, Furukawa S, Mandel U, Joshi HJ, Dworkin L, Hansen L, David L, Iverson TM, Bensing BA, Sullam PM, Varki A, de Vries E, de Haan CAM, Vincentelli R, Henrissat B, Vakhrushev SY, Clausen H, Narimatsu Y. Display of the human mucinome with defined O-glycans by gene engineered cells. Nature Communications. 2021. 12(1):4070. doi.org/10.1038/s41467-021-24366-4
31. van Houtum EJ, Büll C, Cornelissen LAM, Adema GJ. Siglec signaling in the tumor microenvironment. Frontiers in Immunology. 2021. 12:790317. doi.org/10.3389/fimmu.2021.790317
30. Visser EA, Moons SJ, Timmermans SBP, de Jong H, Boltje TJ, Büll C. Sialic acid O-acetylation: From biosynthesis to roles is health and disease. Journal of Biological Chemistry. 2021. 297(2):100906. doi.org/10.1016/j.jbc.2021.100906
29. Narimatsu Y, Büll C, Chen YH, Wandall HH, Yang Z, Clausen H. Genetic glycoengineering in mammalian cells. Journal of Biological Chemistry. 2021. 296:100448. doi.org/10.1016/j.jbc.2021.100448
28. Balneger N, Kroesen M, Lindau D, Wassink M, Boon L, den Brok MH, Büll C, Adema GJ. Generation of αCD11b-CpG antibody conjugates for the targeted stimulation of myeloid cells. Journal of Controlled Release. 2021. 332:148-159. doi.org/10.1016/j.jconrel.2021.02.017
27. Pijnenborg JFA, Visser E, Noga M, Rossing E, Veizaj R, Lefeber DJ, Büll C, Boltje TJ. Cellular fucosylation inhibitors based on fluorinated fucose-1-phosphates. Chemistry – A European Journal. 2021. 27(12):4022-4027. doi.org/10.1002/chem.202005359
Ealier work
26. Büll C, Joshi HJ, Clausen H, Narimatsu Y. Cell-based glycan arrays - A practical guide to dissect the human glycome. STAR Protocols. 2020. 1(1):100017. doi.org/10.1016/j.xpro.2020.100017
25. van de Wall S, Santegoets KC, van Houtum EJ, Büll C, Adema GJ. Sialoglycans and Siglecs can shape the tumor immune microenvironment. Trends in Immunology. 2020. 41(4):272-283. doi.org/10.1016/j.it.2020.02.001
24. Dabelsteen S, Pallesen EMH, Marinova IN, Nielsen MI, Adamopoulou M, Rømer TB, Levann A, Aagaard DT, Bennett EP, Andersen MM, Büll C, Moons SJ, Boltje TJ, Ye Z, Clausen H, Vakhrushev SY, Bagdonaite I, Wandall HH. Essential functions of glycans in human epithelia dissected by a CRISPR/Cas9-engineered human organotypic skin model. Developmental Cell. 2020. 54(5):669-684. doi.org/10.1016/j.devcel.2020.06.039
23. Narimatsu Y, Joshi HJ, Nason R, Van Coillie J, Karlsson R, Sun L, Ye Z, Chen YH, Schjoldager KT, Steentoft C, Furukawa S, Bensing BA, Sullam PM, Thompson AJ, Paulson JC, Büll C, Adema GJ, Mandel U, Hansen L, Bennett EP, Varki A, Vakhrushev SY, Yang Z, Clausen H. An atlas of human glycosylation pathways enables display of the human glycome by gene engineered cells. Molecular Cell. 2019. 75(2):394-407. doi.org/10.1016/j.devcel.2020.06.039
22. Moons SJ, Adema GJ, Derks MT, Boltje TJ, Büll C. Sialic acid glycoengineering using N-acetylmannosamine and sialic acid analogues. Glycobiology. 2019. 29(6):433-445. doi.org/10.1093/glycob/cwz026
21. van den Bijgaart RJE, Kroesen M, Wassink M, Brok IC, Kers-Rebel ED, Boon L, Heise T, van Scherpenzeel M, Lefeber DJ, Boltje TJ, den Brok MH, Hoogerbrugge PM, Büll C, Adema GJ. Combined sialic acid and HDAC inhibitor treatment upregulates the neuroblastoma antigen GD2. Journal of Biological Chemistry. 2019. 294(12):4437-4449. doi.org/10.1074/jbc.RA118.002763
20. Jaeger M, Pinelli M, Borghi M, Constantini C, Dindo M, van Emst L, Puccetti M, Pariano M, Ricaño-Ponce I, Büll C, Gresnigt MS, Wang X, Gutierrez Achury J, Jacobs CWM, Xu N, Doppenberg M, Arts P, Joosten LAB, van de Veerdonk FL, Veltman J, ten Oever J, Kullberg BJ, Feng M, Adema GJ, Wijmenga C, Kumar V, Sobel J, Gillissen C, Romani L, Netea MG. Systems genomics approach identifies SIGLEC15 as a novel susceptibility factor in recurrent vulvovaginal candidiasis. Science Translational Medicine. 2019. 11(496):eaar3558. doi.org/10.1126/scitranslmed.aar3558
19. Santegoets KC, Gielen PR, Büll C, Schulte BM, Kers-Rebel ED, Küsters B, Bossman SA, ter Laan M, Wesseling P, Adema GJ. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma. Cancer Immunology Immunotherapy. 2019. 68:937-949. doi.org/10.1007/s00262-019-02332-w
18. Heise T, Pijnenborg JFA, Büll C, van Hilten N, Kers-Rebel ED, Balneger N, Elferink H, Adema GJ, Boltje TJ. Potent Metabolic Sialyltransferase inhibitors based on C-5 modified fluorinated sialic acids. Journal of Medicinal Chemistry. 2019. 62(2):1014-1021. doi.org/10.1021/acs.jmedchem.8b01757
17. Büll C, Boltje TJ, Balneger N, Weischer S, Wassink M, van Gemst J, Bloemendal VR, Boon L, van der Vlag J, Heise T, den Brok MH, Adema GJ. Sialic acid blockade suppresses tumor growth by enhancing T cell-mediated tumor immunity. Cancer Research. 2018. 78(13):3574-3588. doi.org/10.1158/0008-5472.CAN-17-3376
16. Kullaya V, de Jonge MI, Langereis JD, van der Gaast-de Jongh CE, Büll C, Adema GJ, Lefeber DJ, Cremers AJ, Mmbaga BT, de Groot PG, de Mast Q, van der Ven AJ. Desialylation of platelets by pneumococcal neuraminidase A induces ADP-dependent platelet hyper-reactivity. Infection and Immunity. 2018. 86(10):e00213-e00218. doi.org/10.1128/iai.00213-18
15. Heise T, Langereis JD, Rossing E, de Jonge MI, Adema GJ, Büll C, Boltje TJ. Selective inhibition of sialic acid-based molecular mimicry in Haemophilus influenzae abrogates serum resistance. 2018. Cell Chemical Biology. 2018. 25(10):1279-1285. doi.org/10.1016/j.chembiol.2018.05.018
14. Büll C, Heise T, van Hilten N, Pijnenborg JFA, Bloemendal V, Gerrits L, Kers-Rebel ED, Ritschel T, den Brok MH, Adema GJ. Boltje TJ. Steering sialic acid-Siglec interactions of living cells using bioorthogonal chemistry. Angewandte Chemie International Edition. 2017. 56(12):3309-3313. doi.org/10.1002/anie.201612193
13. Büll C, Collado-Camps E, Kers-Rebel ED, Heise T, Søndergaard JN, den Brok MH, Schulte BM, Boltje TJ, Adema GJ. Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation. Immunology and Cell Biology. 2017. 95(4):408-415. doi.org/10.1038/icb.2016.105
12. Heise T, Büll C, Beurskens DM, Rossing E, de Jonge MI, Adema GJ, Boltje TJ, Langereis JD. Metabolic oligosaccharide engineering with alkyne sialic acids confers neuraminidase resistance and inhibits influenza reproduction. Bioconjugate Chemistry. 2017. 28(7):1811-1815. doi.org/10.1021/acs.bioconjchem.7b00224
11. Büll C, Heise T, Adema GJ, Boltje TJ. Sialic acid mimetics to target the sialic acid-Siglec axis. Trends in Biochemical Sciences. 2016. 41(6):519-531. doi.org/10.1016/j.tibs.2016.03.007
10. Kroesen M, Büll C, Gielen PR, Brok IC, Armandari I, Wassink M, Looman MW, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ. Anti-GD2 mAb and vorinostat synergize in the treatment of neuroblastoma. Oncoimmunology. 2016. 5(6):e1164919. doi.org/10.1080/2162402X.2016.1164919
9. Gram AM, Oosenbrug T, Lindenbergh MFS, Büll C, Comvalius A, Dickson KJI, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MHM, Tscharke DC, Hutt-Fletcher LM, Wiertz EJHJ, Hoeben RC, Ressing ME. The Epstein-Barr virus glycoprotein GP150 forms an immune-evasive glycan shield at the surface of infected cells. PLOS Pathogens. 2016. 12(4):e1005550. doi.org/10.1371/journal.ppat.1005550
8. den Brok MH, Büll C, Wassink M, de Graaf AM, Wagenaars A, Minderman M, Thakur M, Amigorena S, Rijke EO, Schrier CC, Adema GJ. Saponin-based adjuvant-induced immunity is dependent on intracellular lipid bodies in dendritic cells. Nature Communications. 2016. 7:13324. doi.org/10.1038/ncomms13324
7. Büll C, Boltje TJ, van Dinther E, Peters T, de Graaf AM, Leusen JH, Kreutz M, Figdor CG, den Brok MH, Adema GJ. Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread. ACS Nano. 2015. 9(1):733-745
6. Riemersma M, Sandrock J, Boltje TJ, Büll C, Heise T, Ashikov A, Adema GJ, van Bokhoven H, Lefeber DJ. Disease mutations in CMP-sialic acid transporter SLC35A1 result in abnormal α-dystroglycan O-mannosylation, independent from sialic acid. Human Molecular Genetics. 2015. 24(8):2241-2246. doi.org/10.1093/hmg/ddu742
5. Büll C, Heise T, Beurskens DM, Riemersma M, Ashikov A, Rutjes FP, van Kuppevelt TH, Lefeber DJ, den Brok MH, Adema GJ, Boltje TJ. Sialic acid glycoengineering using an unnatural sialic acid for the detection of sialoglycan biosynthesis defects and on-cell synthesis of siglec ligands. ACS Chemical Biology. 2015. 10(10):2353-2363. doi.org/10.1021/nn5061964
4. Büll C, Stoel MA, den Brok MH, Adema GJ. Sialic acids sweeten a tumor's life. Cancer Research. 2014. 74(12):3199-3204. doi.org/10.1158/0008-5472.CAN-14-0728
3. Büll C, den Brok MH, Adema GJ. Sweet escape: Sialic acids in tumor immune evasion. Biochimica et Biophysica Acta - Reviews on Cancer. 2014. 1846(1):238-246. doi.org/10.1016/j.bbcan.2014.07.005
2. Büll C, Boltje TJ, Wassink M, de Graaf AM, van Delft FL, den Brok MH, Adema GJ. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Molecular Cancer Therapeutics. 2013. 12(10):1935-1946. doi.org/10.1158/1535-7163.MCT-13-0279
1. Leunissen EH, Nair AV, Büll C, Lefeber DJ, van Delft FL, Bindels RJ, Hoenderop JG. The epithelial calcium channel TRPV5 is regulated differentially by klotho and sialidase. Journal of Biological Chemistry. 2013. 288(41):29238-29246. doi.org/10.1074/jbc.M113.473520